Disease · MONDO_0006292

malignant mesothelioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. malignant mesothelioma. Diseases, record MONDO_0006292. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006292

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: malignant mesothelioma; Open Targets
Open Targets ID: MONDO_0006292; Open Targets
Other names: advanced malignant mesothelioma, asbestos-related malignant mesothelioma, diffuse malignant mesothelioma, malignant mesothelial neoplasm, malignant mesothelial tumor, malignant mesothelial tumour, malignant mesothelioma (disease), malignant neoplasm of mesothelium, malignant neoplasm of the mesothelium, malignant tumor of mesothelium, malignant tumor of the mesothelium, malignant tumour of mesothelium, malignant tumour of the mesothelium, mesothelioma, malignant, mesothelioma, somatic; Open Targets
Disease Ontology: DOID:1790; Disease Ontology
MeSH: C562839; MeSH
NCI Thesaurus: C4456; NCI Thesaurus
Orphanet: ORPHA:50251; Orphanet
Highest stage of its drugs: Approval, for 1 of its 37 drugs, from EMA Human Drugs; Open Targets

Drugs37

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IPILIMUMAB	CHEMBL1789844	Antibody	Approval	EMA Human Drugs	2	1	1	Drugs and targets
TREMELIMUMAB	CHEMBL2108658	Antibody	Phase 3	TTD	4	3	3	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	7	7	7	Drugs and targets
PEMETREXED	CHEMBL225072	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
GEFITINIB	CHEMBL939	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IMATINIB MESYLATE	CHEMBL1642	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
OLAPARIB	CHEMBL521686	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 37

See all 37 drugs

Targets133

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FLT1	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
EGFR	Epidermal growth factor receptor	3	Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	3	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor beta	3	Platelet-derived growth factor receptor beta inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
RET	Proto-oncogene tyrosine-protein kinase receptor Ret	3	Tyrosine-protein kinase receptor RET inhibitor	Phase 2	https://conductscience.org/library/genes/5979	Drugs and targets
TUBA1A	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets

1 to 10 of 133

See all 133 targets

Trials33

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01843374	Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma	Phase 2	571	2017-08-17	Unresectable Pleural or Peritoneal Malignant Mesothelioma	TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT01362790	SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma	Phase 1/2	55	2019-06-06	Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms	CYCLOPHOSPHAMIDE, PENTOSTATIN, SS1(DSFV)-PE38	Its record names the disease	ClinicalTrials.gov
NCT00295503	Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma	Phase 2	53	2017-01-05	Mesothelioma	BEVACIZUMAB, CISPLATIN, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT00309946	Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery	Phase 2	51	2013-09-10	Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma	CEDIRANIB MALEATE	Its record names the disease	ClinicalTrials.gov
NCT00629343	Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide	Phase 1	27	2025-06-05	Soft Tissue Sarcoma, Mesothelioma	AZACITIDINE, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00597116	An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma	Phase 2	25	2012-10-15	Mesothelioma	VANDETANIB	Its record names the disease	ClinicalTrials.gov
NCT03531840	Olaparib in People With Malignant Mesothelioma	Phase 2	23	2021-03-11	Mesothelioma	OLAPARIB	Its record names the disease	ClinicalTrials.gov
NCT01861301	Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma	Phase 2	18	2016-10-24	Epithelioid Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma, Stage II Pleural Mesothelioma, Stage III Pleural Mesothelioma, Stage IV Pleural Mesothelioma	TIVANTINIB	Its record names the disease	ClinicalTrials.gov
NCT03319537	Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma	Phase 1/2	9	2024-05-23	Mesothelioma	CISPLATIN, PEMETREXED, PEVONEDISTAT	Its record names the disease	ClinicalTrials.gov
NCT01204203	Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)	Phase 2	8	2017-05-24	Mesothelioma	ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov

1 to 10 of 33

See all 33 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
TREMELIMUMAB vs PLACEBO: deaths from any cause	318 of 382	160 of 189	571	NCT01843374	Trial comparisons
TREMELIMUMAB vs PLACEBO: Number of Participants Reporting Any Adverse Event	364 of 380	179 of 189	569	NCT01843374	Trial comparisons
TREMELIMUMAB vs PLACEBO: Number of Participants Reporting Any Serious Adverse Events	218 of 380	85 of 189	569	NCT01843374	Trial comparisons
TREMELIMUMAB vs PLACEBO: serious adverse events	218 of 380	85 of 189	569	NCT01843374	Trial comparisons
TREMELIMUMAB vs PLACEBO: Number of Participants With Positive Anti-drug Antibodies	15 of 377	0 of 188	565	NCT01843374	Trial comparisons
Vandetanib vs Vinorelbine: serious adverse events	6 of 13	3 of 10	23	NCT00597116	Trial comparisons
Vandetanib vs Vinorelbine: Number of Participants With Disease Control.	0 of 12	5 of 10	22	NCT00597116	Trial comparisons
Vandetanib vs Vinorelbine: Number of Participants With Objective Response.	0 of 12	0 of 10	22	NCT00597116	Trial comparisons

Papers from its trials13

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22831987	RESULT	1	PubMed
41425223	DERIVED	1	PubMed
36104949	DERIVED	1	PubMed
35671201	DERIVED	1	PubMed
33844995	DERIVED	1	PubMed
33161240	DERIVED	1	PubMed
31114846	DERIVED	1	PubMed
30883000	DERIVED	1	PubMed
29773326	DERIVED	1	PubMed
28729154	DERIVED	1	PubMed

1 to 10 of 13

See all 13 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006292

GET https://conductscience.org/api/diseases/v1/MONDO_0006292/drugs?page=2

API reference For AI assistants